1. Home
  2. IFN vs ARVN Comparison

IFN vs ARVN Comparison

Compare IFN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo India Fund Inc. (The)

IFN

India Fund Inc. (The)

HOLD

Current Price

$11.47

Market Cap

504.6M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$9.33

Market Cap

516.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IFN
ARVN
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
504.6M
516.2M
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
IFN
ARVN
Price
$11.47
$9.33
Analyst Decision
Buy
Analyst Count
0
19
Target Price
N/A
$15.05
AVG Volume (30 Days)
124.8K
898.7K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.84
EPS
N/A
1.70
Revenue
N/A
$262,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.51
Revenue Growth
N/A
N/A
52 Week Low
$10.72
$6.97
52 Week High
$15.47
$14.22

Technical Indicators

Market Signals
Indicator
IFN
ARVN
Relative Strength Index (RSI) 37.13 58.81
Support Level $11.40 $7.90
Resistance Level $11.79 $9.65
Average True Range (ATR) 0.08 0.36
MACD -0.03 0.04
Stochastic Oscillator 2.91 73.65

Price Performance

Historical Comparison
IFN
ARVN

About IFN India Fund Inc. (The)

India Fund Inc is a non-diversified closed-end management investment company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: